法布瑞氏症：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國法布瑞氏症市場預計將從 2025 年的 1.26 億美元成長到 2035 年的 2.835 億美元。
• 推動市場成長的因素如下：
• 酵素替代療法和Chaperone療法的擴展
• 新型基因療法與基材減少療法的出現
• 未來市場擴張取決於永續的緩解疾病療法的建立。

法布瑞氏症概述

法布瑞氏症是一種罕見的遺傳性代謝紊亂疾病，會導致進行性性器官衰竭和過早死亡。此病由半乳糖苷酶α基因突變引起，導致溶小體酵素α-半乳糖苷酶A（GALA）缺乏或缺失。這種缺乏會抑制Globotriaosylceramide（Gb3）及其相關Glico的分解，導致Gb3和Glico在溶小體內逐漸累積。這些累積被認為具有細胞毒性、促發炎和促纖維化作用。晚髮型法布瑞氏症患者通常在晚年出現症狀，主要涉及單一器官系統，尤其是心臟。然而，由於法布瑞氏症罕見且臨床表現多樣，因此診斷可能具有挑戰性。

主要亮點

• 據預測，德國法布瑞氏症患者人數將從 2025 年的 1,318 人增加到 2035 年的 1,369 人。
• 法布瑞氏症是一種罕見的 X 連鎖溶小體儲積症，由 α-半乳糖苷酶 A 缺乏所引起。
• 腎臟、心臟和神經系統併發症的進行性是導致長期疾病負擔的因素。
• 早期診斷和基因篩檢導致確診患者數量增加。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Sanofi
• Bio Sidus SA
• Guangzhou Jiayin Biotech Ltd.
• Amicus Therapeutics
• UniQure Biopharma BV
• 4D Molecular Therapeutics
• Chiesi Farmaceutici SpA
• Shire
• Idorsia Pharmaceuticals Ltd.
• Sangamo Therapeutics
• GC Biopharma Corp.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Fabry Disease Market Outlook

Thelansis's "Fabry Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fabry Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Fabry Disease Overview

Fabry disease, a rare genetic metabolic storage disorder, results in the progressive failure of organs and premature death. It arises from a mutation in the galactosidase alpha gene, causing a deficiency or absence of a-galactosidase A (GALA), a lysosomal enzyme. Consequently, this deficiency impairs the breakdown of globotriaosylceramide (Gb3) and related glycosphingolipids, gradually accumulating Gb3 and glycosphingolipids within lysosomes. These accumulations are believed to have cytotoxic, proinflammatory, and profibrotic effects. Patients with late-onset Fabry disease typically manifest symptoms later in life, primarily affecting a single organ system, most commonly the heart. Nevertheless, diagnosing Fabry's disease can be challenging due to its rarity and diverse symptoms.

Key Highlights

• In Germany, prevalent Fabry disease cases are projected to increase from 1,318 in 2025 to 1,369 by 2035.
• Fabry disease is a rare X-linked lysosomal storage disorder resulting from a-galactosidase A deficiency.
• Progressive renal, cardiac, and neurological complications drive long-term disease burden.
• Earlier diagnosis and genetic screening are expanding the identified patient pool.

Market Overview

• The France Fabry disease market is projected to grow from $126M in 2025 to $283.5M by 2035.
• Market growth is driven by:
• Increased uptake of enzyme replacement and chaperone therapies
• Emerging gene therapy and substrate reduction approaches
• Future expansion will depend on durable disease-modifying treatments.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Sanofi
• Bio Sidus SA
• Guangzhou Jiayin Biotech Ltd.
• Amicus Therapeutics
• UniQure Biopharma B.V.
• 4D Molecular Therapeutics
• Chiesi Farmaceutici S.p.A.
• Shire
• Idorsia Pharmaceuticals Ltd.
• Sangamo Therapeutics
• GC Biopharma Corp.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)